BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry’s most advanced graph analytic AI technologies. 

The Problem:

The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don’t come: 

•	The cost of bringing a drug to market is $.8 to $2.8 billion
•	Almost 90% of drugs don’t get there
•	The average time to market is 8.5 YEARS

Our Solution:

We’re applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. 

Our Technology:

The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to “black box” processing and say hello to AI outputs you can explore and understand. 

Join Us in Our Mission:

With our platform’s superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers.

Leap into the next generation of drug development with BullFrog AI.

TEDCO

BullFrog AI

At BullFrog AI, we've always believed in the power of data-driven innovation. Today, we're excited to spotlight our strategic partnership with the Lieber Institute for Brain Development (LIBD), a pioneer in the field of neuropsychiatric research.

LIBD boasts the world's largest repository of postmortem brains, a treasure trove for understanding the complexities of the human brain. 

But what does this mean to clients?

•	bfLEAP™ can ingest proprietary datasets to potentially accelerate CNS initiatives.
•	We’re positioned to leverage cutting-edge insights from LIBD data.

Stay tuned!

https://bullfrogai.com/

See Dr. Kristi Bigos at the WinterBrain Conference


https://winterbrain.org/
Join us this year for the 2024 Winter Conference on Brain Research in Breckenridge, Colorado with all scientific activities taking place at the Beaver Run Resort & Convention Center.

Traditional scientific panels are scheduled from 7:30 to 9:30 a.m., 4:30 to 6:30 p.m., and 7:00 to 8:30 p.m. to accommodate 6-8 simultaneous research tracks. The schedule allows ample time for informal discussions during outdoor activities on and off the mountain. Everyone is welcome to attend Winter Brain, either as a presenter or attendee.

#bullfrogai #KristiBigos #WinterBrain

GAITHERSBURG, Md., Jan. 17, 2024 -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Click here to read more: https://lnkd.in/guMRKWRY

#bullfrogai #LIBD #AIdrugdiscovery

GAITHERSBURG, Md., Jan. 16, 2024 -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This follows the July 2023 announcement of the issuance of U.S. Patent No. 11,712,435 for this invention (link), with issuance of patents expected in additional territories in the future.
Click here to learn more: https://lnkd.in/eWd2MMn7

#bullfrogai #AIdrugdevelopment #oncology

Join us as Vin Singh, Chief Executive Officer of BullFrog AI, presents at the Webull LIVE! Healthcare Webinar on Wednesday, January 17, 2024.

Register here: https://lnkd.in/gu2P3WWh


#BullFrogAI #WebullLIVE #VinSingh #DigitalHealth #ArtificialIntelligence #Healthtech #FutureofHealthcare #Innovation

Meet with Vin Singh, CEO of BullFrog AI at the JP Morgan Healthcare Conference in San Francisco! Learn about out unique approach to AI and machine learning using graph analytics, and our recent partnership with the Lieber Institute for Brain Development, including the largest postmortem brain tissue repository in the world, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data. 

Click here to connect with Vin at JPM: https://lnkd.in/ehACXqbX

#JPMorgan #BullFrogAI #VinSingh #AI #graphanalytics

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.
https://lnkd.in/ddKnBWbr

#BullFrogAI #pharmaceuticaldevelopment #artificialintelligence #machinelearning #technology #drugdevelopment #shareholderletter #CEOupdate #innovation

Happy New Year!! from the BullFrog AI Team!

Happy Holidays from the BullFrog AI Team!!!

We will be closed on December 25th and January 1st.

	Dec '21	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
account payables	68.59K -	101.27K 47.64%	120.54K 19.03%	543.99K 351.30%	636.89K 17.08%	490.71K 22.95%	110.50K 77.48%	103.66K 6.20%	154.54K 49.09%	82.02K 46.93%	91.37K 11.41%
accumulated other comprehensive income loss							3.77M -	-61 100.00%	-1 98.36%	-1 0%	-1 0%
cash and cash equivalents	10.01K -	238.45K 2,281.20%	42.22K 82.30%	57.67K 36.61%	5.42M 9,297.47%	5.46M 0.74%	3.86M 29.37%	2.62M 31.93%	7.01M 167.10%	5.61M 19.92%	4.24M 24.49%
cash and short term investments	10.01K -	238.45K 2,281.20%	42.22K 82.30%	57.67K 36.61%	5.42M 9,297.47%	5.46M 0.74%	3.86M 29.37%	2.62M 31.93%	7.01M 167.10%	5.61M 19.92%	4.24M 24.49%
common stock	272 -	279 2.57%	282 1.08%	40 85.82%	57 42.50%	61 7.02%	61 0%	61 0%	79 29.51%	79 0%	79 0%
deferred revenue	10K -	32K 220.00%	32K 0%	32K 0%	32K 0%	32K 0%	-213.29K 766.53%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt
long term investments
net debt	576.29K -	1.08M 88.08%	1.44M 33.04%	1.52M 5.48%	-5.42M 456.30%	-5.04M 7.07%	-3.64M 27.67%	-2.62M 27.95%	-6.50M 147.78%	-5.61M 13.68%	-4.24M 24.49%
net receivables
other assets
other current assets							352.43K -	145.88K 58.61%	632.60K 333.64%	457.36K 27.70%	358.54K 21.61%
other current liabilities	708.45K -	1.40M 97.24%	1.68M 20.51%	1.97M 16.75%	940.38K 52.17%	391.81K 58.34%	122.26K 68.80%	80.69K 34.00%	182.83K 126.58%	609.48K 233.35%	687.66K 12.83%
other liabilities
other non current assets								0.00 -	0.00 104.38%
other non current liabilities
othertotal stockholders equity	587.19K -	1.05M 78.19%	1.29M 23.28%	1.34M 4.01%	10.35M 671.31%	12.11M 16.98%	12.23M 1.00%	12.35M 0.98%	18.48M 49.67%	18.67M 1.04%	18.87M 1.08%
preferred stock				1 -	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%
property plant equipment net		8.58K -	8.14K 5.14%	7.70K 5.42%	7.27K 5.60%	6.84K 5.93%	6.41K 6.30%	5.97K 6.74%	5.54K 7.21%	5.11K 7.78%	4.68K 8.43%
retained earnings	-1.60M -	-2.94M 84.07%	-3.70M 26.02%	-4.40M 18.78%	-5.72M 30.13%	-7.21M 25.86%	-8.46M 17.39%	-9.75M 15.33%	-11.68M 19.69%	-13.29M 13.80%	-15.05M 13.27%
short term debt	586.30K -	1.32M 125.54%	1.48M 12.24%	1.58M 6.37%	310.89K 80.31%	423.05K 36.08%	213.29K 49.58%		507.15K -
short term investments
tax assets
tax payables
total assets	10.01K -	262.03K 2,516.68%	65.36K 75.06%	80.37K 22.97%	6.23M 7,655.59%	6.04M 3.07%	4.21M 30.24%	2.78M 34.12%	7.65M 175.48%	6.08M 20.56%	4.60M 24.26%
total current assets	10.01K -	253.45K 2,430.99%	57.22K 77.43%	72.67K 27.01%	6.23M 8,467.25%	6.04M 3.06%	4.21M 30.27%	2.77M 34.17%	7.64M 175.87%	6.07M 20.57%	4.60M 24.28%
total current liabilities	1.02M -	2.15M 111.39%	2.48M 15.06%	3.14M 26.59%	1.61M 48.71%	1.14M 29.06%	446.05K 60.93%	184.35K 58.67%	844.53K 358.11%	691.49K 18.12%	779.04K 12.66%
total debt	586.30K -	1.32M 125.54%	1.48M 12.24%	1.58M 6.37%		423.05K -	213.29K 49.58%		507.15K -
total investments
total liabilities	1.02M -	2.15M 111.39%	2.48M 15.06%	3.14M 26.59%	1.61M 48.71%	1.14M 29.06%	446.05K 60.93%	184.35K 58.67%	844.53K 358.11%	691.49K 18.12%	779.04K 12.66%
total liabilities and stockholders equity	10.01K -	262.03K 2,516.68%	65.36K 75.06%	80.37K 22.97%	6.23M 7,655.59%	6.04M 3.07%	4.21M 30.24%	2.78M 34.12%	7.65M 175.48%	6.08M 20.56%	4.60M 24.26%
total non current assets		8.58K -	8.14K 5.14%	7.70K 5.42%	7.27K 5.60%	6.84K 5.93%	6.41K 6.30%	5.97K 6.74%	5.54K 7.21%	5.11K 7.78%	4.68K 8.43%
total non current liabilities
total stockholders equity	-1.01M -	-1.89M 87.52%	-2.41M 27.54%	-3.06M 26.68%	4.62M 251.24%	4.90M 5.98%	3.77M 23.09%	2.59M 31.22%	6.80M 162.49%	5.39M 20.86%	3.82M 29.00%

COM:BULLFROGAI

Bullfrog AI Holdings, Inc.

Last Close

2.01

22/11 21:00

Market Cap

12.64M

Beta: -

Volume Today

91.00K

Avg: -

Preview